Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × Nivolumab × 1 year × Clear all

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05255601 2026-02-25

RELATIVITY-069

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Active not recruiting

30 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

27 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03038672 2025-11-10

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase 2 Active not recruiting

54 enrolled 12 charts

Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04205409 2025-11-03

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2 Active not recruiting

20 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase 1/2 Active not recruiting

36 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03843294 2025-07-03

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

Phase 1 Active not recruiting

18 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse

NCT03311958 2025-04-06

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

Phase EARLY_PHASE1 Completed

15 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

RELATIVITY-069

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance